Frontier Development PLC — Regulatory Filings 2018

Jun 1, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0073Q

Frontier Developments PLC

01 June 2018

1 June 2018

Frontier Developments plc

(the "Company")

Total Voting Rights

In accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that its issued share capital at 31 May 2018 consisted of 38,660,368 ordinary shares of 0.5p each ("Ordinary Shares").

The Company does not currently hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 38,660,368.

The above figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

Frontier Developments	+44 (0)1223 394 300
David Braben, CEO David Walsh, COO Alex Bevis, CFO
Liberum - Nomad and Joint Broker	+44 (0)203 100 2000
Neil Patel / Cameron Duncan
Finncap	+44 (0) 207 220 0500
Matt Goode/Giles Rolls
Tulchan Communications	+44 (0) 207 353 4200
James Macey White/Matt Low

About Frontier Developments plc 

Frontier Developments plc, listed on the AIM stock market (AIM: FDEV), is a leading independent creator of self-published videogame franchises founded in 1994 by David Braben, co-author of the seminal 'Elite' game. Based in Cambridge, UK, Frontier uses its proprietary 'COBRA' game development technology to create innovative videogames for home consoles and personal computers.  Frontier's LEI number: 213800B9LGPWUAZ9GX18.

www.frontier.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVRVFLBBVQFEBBV